Fuente: Labiotech Lugar: Top Pharma Strategy Find out what Novartis' pipeline strategy since it spun off its biosimilars and generics business Sandoz, and engage in intensive dealmaking.
The post Novartis’ strategy in 2026: rebuilding the pipeline after Entresto  appeared first on Labiotech.eu.
© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.